BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35730597)

  • 21. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
    Gagnon N; Mansour S; Bitton Y; Bourdeau I
    Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Catecholamine-Secreting Tumors in Pediatric Patients With Cyanotic Congenital Heart Disease.
    Agarwal S; Jindal I; Balazs A; Paul D
    J Endocr Soc; 2019 Nov; 3(11):2135-2150. PubMed ID: 31687640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma.
    Jiang J; Zhang J; Pang Y; Bechmann N; Li M; Monteagudo M; Calsina B; Gimenez-Roqueplo AP; Nölting S; Beuschlein F; Fassnacht M; Deutschbein T; Timmers HJLM; Åkerström T; Crona J; Quinkler M; Fliedner SMJ; Liu Y; Guo J; Li X; Guo W; Hou Y; Wang C; Zhang L; Xiao Q; Liu L; Gao X; Burnichon N; Robledo M; Eisenhofer G
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32750708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
    Toledo RA
    Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma.
    Eckardt L; Prange-Barczynska M; Hodson EJ; Fielding JW; Cheng X; Lima JDCC; Kurlekar S; Douglas G; Ratcliffe PJ; Bishop T
    Endocr Relat Cancer; 2021 Oct; 28(12):757-772. PubMed ID: 34658364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.
    Remacha L; Pirman D; Mahoney CE; Coloma J; Calsina B; Currás-Freixes M; Letón R; Torres-Pérez R; Richter S; Pita G; Herráez B; Cianchetta G; Honrado E; Maestre L; Urioste M; Aller J; García-Uriarte Ó; Gálvez MÁ; Luque RM; Lahera M; Moreno-Rengel C; Eisenhofer G; Montero-Conde C; Rodríguez-Antona C; Llorca Ó; Smolen GA; Robledo M; Cascón A
    Am J Hum Genet; 2019 Apr; 104(4):651-664. PubMed ID: 30929736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.
    Crona J; Lamarca A; Ghosal S; Welin S; Skogseid B; Pacak K
    Endocr Relat Cancer; 2019 May; 26(5):539-550. PubMed ID: 30893643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paraganglioma with High Levels of Dopamine, Dopa Decarboxylase Suppression, Dopamine β-hydroxylase Upregulation and Intra-tumoral Melanin Accumulation: A Case Report with a Literature Review.
    Nezu M; Hirotsu Y; Amemiya K; Tateno T; Takizawa S; Inoue M; Mochizuki H; Hosaka K; Chik C; Oyama T; Omata M
    Intern Med; 2023 Jul; 62(13):1895-1905. PubMed ID: 36384901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma.
    Hadrava Vanova K; Pang Y; Krobova L; Kraus M; Nahacka Z; Boukalova S; Pack SD; Zobalova R; Zhu J; Huynh TT; Jochmanova I; Uher O; Hubackova S; Dvorakova S; Garrett TJ; Ghayee HK; Wu X; Schuster B; Knapp PE; Frysak Z; Hartmann I; Nilubol N; Cerny J; Taieb D; Rohlena J; Neuzil J; Yang C; Pacak K
    J Natl Cancer Inst; 2022 Jan; 114(1):130-138. PubMed ID: 34415331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of metastatic pheochromocytoma and paraganglioma in
    Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
    J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients.
    Calsina B; Currás-Freixes M; Buffet A; Pons T; Contreras L; Letón R; Comino-Méndez I; Remacha L; Calatayud M; Obispo B; Martin A; Cohen R; Richter S; Balmaña J; Korpershoek E; Rapizzi E; Deutschbein T; Vroonen L; Favier J; de Krijger RR; Fassnacht M; Beuschlein F; Timmers HJ; Eisenhofer G; Mannelli M; Pacak K; Satrústegui J; Rodríguez-Antona C; Amar L; Cascón A; Dölker N; Gimenez-Roqueplo AP; Robledo M
    Genet Med; 2018 Dec; 20(12):1652-1662. PubMed ID: 30008476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study.
    Ma X; Li M; Tong A; Wang F; Cui Y; Zhang X; Zhang Y; Chen S; Li Y
    Front Endocrinol (Lausanne); 2020; 11():574662. PubMed ID: 33362715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Case of Paraganglioma with Cyanotic Congenital Heart Disease.
    Wahab NA; Chien BH; Omar MR; Aziz AA; Mustafa N; Sukor N; Kamaruddin NA
    Acta Med Indones; 2021 Jan; 53(1):77-81. PubMed ID: 33818409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma.
    Buffet A; Zhang J; Rebel H; Corssmit EPM; Jansen JC; Hensen EF; Bovée JVMG; Morini A; Gimenez-Roqueplo AP; Hes FJ; Devilee P; Favier J; Bayley JP
    J Clin Endocrinol Metab; 2021 Jan; 106(2):459-471. PubMed ID: 33180916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic IDH1 Hotspot Variants in Chinese Patients With Pheochromocytomas and Paragangliomas.
    Li M; He Y; Pang Y; Zhang J; Feng Y; He Y; Xu X; Wei Y; Zhong D; Deng W; Wang L; Yan B; Jiang Y; Xu N; Cai H; Wen Y; Ning J; Liu Y; Gao X; Shan Z; Liu L; Teng X; Richter S; Jiang J
    J Clin Endocrinol Metab; 2023 Apr; 108(5):1215-1223. PubMed ID: 36355572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression.
    Tomić TT; Olausson J; Rehammar A; Deland L; Muth A; Ejeskär K; Nilsson S; Kristiansson E; Wassén ON; Abel F
    PLoS Genet; 2020 Jun; 16(6):e1008803. PubMed ID: 32511227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of body composition and genotype on haemodynamics during surgery for pheochromocytoma and paraganglioma.
    Pang Y; Li M; Jiang J; Chen X; Fu Y; Wang C; He Y; Zhao Y; Wang Y; Guan X; Zhang L; Xu X; Gan Y; Liu Y; Xie Y; Tang T; Wang J; Xie B; Liang Z; Chen D; Liu H; Chen C; Eisenhofer G; Liu L; Yi X; Chen BT
    J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2843-2853. PubMed ID: 36068986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2
    Pang Y; Gupta G; Yang C; Wang H; Huynh TT; Abdullaev Z; Pack SD; Percy MJ; Lappin TRJ; Zhuang Z; Pacak K
    BMC Cancer; 2018 Mar; 18(1):286. PubMed ID: 29534684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Special situations in pheochromocytomas and paragangliomas: pregnancy, metastatic disease, and cyanotic congenital heart diseases.
    Araujo-Castro M; Nattero Chavez L; Martínez Lorca A; Molina-Cerrillo J; Alonso-Gordoa T; Pascual-Corrales E
    Clin Exp Med; 2022 Aug; 22(3):359-370. PubMed ID: 34591219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
    Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
    Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.